HOME >> MEDICINE >> NEWS
European trial finds old lung cancer treatment may still be best

The first clinical trial to compare directly two of the most widely-used drugs in advanced lung cancer, cisplatinin and carboplatin (both in combination with paclitaxel) have concluded that the older drug, cisplatin, is the better treatment.

Patients given cisplatin and paclitaxel had better survival rates and their quality of life was just as good as patients receiving carboplatin and paclitaxel.

The phase III multi-national European trial involving 618 patients with advanced non small-cell lung cancer (NSCLC) is reported in the new issue of Annals of Oncology.*

Cisplatin tends to be the preferred standard chemotherapy for lung cancer in Europe, but in the USA carboplatin is normally used. The new findings are in contrast to a recent similar study in the USA** where a four-arm trial comparing a range of treatments showed no advantage for any one chemotherapy combination over another.

In the European trial the response rates to the two treatments were similar - 28% in the cisplatin/paclitaxel arm and 25% in the carboplatin/paclitaxel arm, but the median survival in the cisplatin arm was significantly better at 9.8 months compared with 8.5 months. The one-year survival rate was 38% in the cisplatin/paclitaxel arm compared with 33% in the carboplatin/paclitaxel arm and the two-year survival rate was 15% and 9% respectively.

Lead investigator Dr Rafael Rosell from the Hospital Germans Trias i Pujol in Barcelona, Spain said: "This large European randomised study can contribute greatly to resolving the longstanding debate on the superiority of carboplatin or cisplatin-based chemotherapy in lung cancer. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should be the first treatment option." However, Dr Rosell stressed that paclitaxel/carboplatin was still a viable alternative.

In an acco
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-153-677-2181
European Society for Medical Oncology
9-Oct-2002


Page: 1 2

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: European trial finds old lung cancer treatment may still best

(Date:3/1/2015)... (PRWEB) March 01, 2015 Ticket Down is ... in Chicago at Soldier Field. Deadheads have been ... in January. , Grateful Dead was formed 50 years ago ... were together as one until the untimely death of Jerry ... combining different genres including blues, reggae, rock, bluegrass, folk, space ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 “ The Barrel ... monthly Tech Report, which takes a look at the latest ... Tropeano, the host of NewsWatch and a technology expert, conducted ... spiral adds flavor to drinks. , According to Home Distillation ... the best spirits. Well, there’s a pretty cool product that’ll ...
(Date:2/28/2015)... 2015 In recent years Medical Marijuana has ... physicians as a way for them to expand their patient ... as medicine. Since the FDA still lists Cannabis as a ... to licensed physicians that can help guide them when ... Malka in Santa Cruz, CA is a leader in ...
(Date:2/28/2015)... With their commitment to achieving physical results and ... to their already robust library of oblique exercises. “Rope ... as, is often performed on a stationary piece of ... relatively safe manner and can be performed by individuals ... of “Rope Pulls” is located in the oblique exercises ...
(Date:2/28/2015)... 2015 Mew and Company, a Vancouver ... now provide business consulting services in addition to a ... planning and succession planning. Company finances are a complicated ... On top of this, complex Canadian tax laws can ... As a result, Mew and Company works to advise ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
(Date:2/27/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its first quarter ended December 31, ... December 31, 2014, revenue was $1,336,685. Operating expenses were ... $0.02 per share.  Covalon,s President and ... pleased with the significant progress we have made over ...
(Date:2/27/2015)... , Feb. 27, 2015  Bionik Laboratories Corp. ... "Company"), announced today that it acquired Bionik Laboratories, Inc., ... and completed the sale to qualified accredited investors of ... aggregate gross proceeds of approximately $6.2 million. Shares of ... on the OTC Markets under the symbol "DWTPD" until ...
(Date:2/26/2015)... Feb. 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... 5,250,000 shares of its common stock at a price ... proceeds to Tandem from this offering are expected to ... and other estimated offering expenses payable by Tandem. All ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
Cached News: